SNS-595: Started Phase I

Sunesis began an open-label, dose-escalation Phase I trial

Read the full 86 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE